Homepage Top Section2

The decision comes as BioNTech has chosen not to participate further in the programme under the existing collaboration agreement. Despite this change, Genmab will still be required to

Classified as human IL-12 and -23 antagonists, Steqeyma and Steqeyma are I.V. biosimilar products to reference medicine Stelara. The treatment is authorised for use in adults with moderately

The funding initiative was spearheaded by Fairmount and Venrock Healthcare Capital Partners, with contributions from Driehaus Capital Management, Deep Track Capital, Franklin Templeton, Braidwell and RTW Investments. The

The company will leverage its AbReptor protein degradation platform for advancing the programmes across various oncology indications with potential applications in other areas. STIC Investments and DSC Investment

Formerly known as ALPHA-1062, the therapy is said to have a dual mechanism of action aimed at improving tolerability and maintaining the efficacy of galantamine, its active moiety.

This treatment is intended for patients for whom topical corticosteroids are either not adequate or suitable. An investigational topical pan-JAK inhibitor, delgocitinib cream works by inhibiting the JAK-STAT

Ackermans & van Haaren spearheaded the investment round, with participation from both new investors including Driehaus Capital Management and Quest for Growth. Current investors namely BioGeneration Ventures, Capricorn

AbbVie Ventures led the investment round and, as part of its commitment, the company’s associate director Danjuma Quarless will join the board of directors of Oisín. As part

The designation comes after the FDA reviewed the available initial clinical data showing AIC100’s potential to treat recurrent ATC. RMAT designation is aimed at expediting the development and